RxDoctor Payments Data

Theresa Henderson, MD

Pulmonary Disease · Los Angeles, CANPI 1497878177

Payments from drug & device makers

$878in general payments, 2019–2025

Across 10 payments — averaging $87.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$260
  • Novartis$137
  • Amgen$125
  • Boehringer Ingelheim$118
  • E.r. Squibb & Sons, L.L.C.$100
  • Actelion Pharmaceuticals US, Inc.$83
  • plus $56 from 3 others

What the payments were for

  • Food & beverage$878100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$878 in reported general payments places this provider in the 40th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$9,448
Medicare patients
22
Services billed
69

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban65$22,045
ProcritEpoetin Alfa24$14,165
EpogenEpoetin Alfa27$8,800
TradjentaLinagliptin16$4,187
Pantoprazole Sodium19$1,300
Albuterol Sulfate HfaAlbuterol Sulfate15$723
Amlodipine Besylate54$720
Memantine Hcl14$684
Sodium Chloride0.9 % Sodium Chloride27$610
Atorvastatin Calcium26$475
Insulin Glargine-Yfgn12$449
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate12$410
Rosuvastatin Calcium27$370
Losartan Potassium28$227
Tamsulosin Hcl21$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonProcrit$16$14,16524 claims
AmgenEpogen$125$8,80027 claims
Boehringer IngelheimTradjenta$118$4,18716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →